AntiCTLA-4 antibody therapy: Immune monitoring during clinical development of a novel immunotherapy Journal Article
| Authors: | Callahan, M. K.; Wolchok, J. D.; Allison, J. P. |
| Article Title: | AntiCTLA-4 antibody therapy: Immune monitoring during clinical development of a novel immunotherapy |
| Abstract: | Cytotoxic T-lymphocyte-associated antigen (CTLA-4), also known as CD152, is a co-inhibitory molecule that functions to regulate T-cell activation. Antibodies that block the interaction of CTLA-4 with its ligands B7.1 and B7.2 can enhance immune responses, including antitumor immunity. Two CTLA-4blocking antibodies are presently under clinical investigation: ipilimumab and tremelimumab. CTLA-4 blockade has shown promise in treatment of patients with metastatic melanoma, with a recently completed randomized, double-blind phase III trial demonstrating a benefit in overall survival (OS) in the treated population. However, this approach appears to benefit only a subset of patients. Understanding the mechanism(s) of action of CTLA-4 blockade and identifying prognostic immunologic correlates of clinical endpoints to monitor are presently areas of intense investigation. Several immunologic endpoints have been proposed to correlate with clinical activity. This review will focus on the endpoints of immune monitoring described in studies to date and discuss future areas of additional work needed. © 2010 Elsevier Inc. All rights reserved. |
| Keywords: | cancer survival; survival rate; overall survival; review; nonhuman; antineoplastic agents; cancer patient; temozolomide; methodology; antineoplastic agent; transcription factor foxp3; cd8+ t lymphocyte; biological marker; prostate specific antigen; biological markers; metabolism; dacarbazine; glycoprotein gp 100; ipilimumab; ticilimumab; cancer immunotherapy; melanoma; skin neoplasms; granulocyte macrophage colony stimulating factor; drug effect; monoclonal antibody; prostate cancer; skin tumor; blood; cd4+ cd25+ t lymphocyte; regulatory t lymphocyte; immunology; antibodies, monoclonal; drug mechanism; t-lymphocytes, regulatory; ny eso 1 antigen; hla dr antigen; hla-dr antigens; tumor immunity; melan a; th17 cell; monophenol monooxygenase; immunological monitoring; antigens, cd; peptide vaccine; cytotoxic t lymphocyte antigen 4; granulocyte macrophage colony stimulating factor vaccine; leukocyte antigen; t lymphocyte activation; cd45 antigen; monitoring, immunologic; lymphocyte count; th17 cells; budesonide; cp-675,206; cytotoxic t-lymphocyte antigen 4; inducible t cell co stimulator; inducible t-cell co-stimulator; t lymphocyte antigen; antigens, cd45; antigens, differentiation, t-lymphocyte |
| Journal Title: | Seminars in Oncology |
| Volume: | 37 |
| Issue: | 5 |
| ISSN: | 0093-7754 |
| Publisher: | Elsevier Inc. |
| Date Published: | 2010-10-01 |
| Start Page: | 473 |
| End Page: | 484 |
| Language: | English |
| DOI: | 10.1053/j.seminoncol.2010.09.001 |
| PUBMED: | 21074063 |
| PROVIDER: | scopus |
| PMCID: | PMC3008567 |
| DOI/URL: | |
| Notes: | --- - "Cited By (since 1996): 1" - "Export Date: 20 April 2011" - "CODEN: SOLGA" - "Source: Scopus" |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work